SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on January 12, 2015. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware with principal executive offices in San Diego, CA.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a management presentation rather than a financial statement.
Material Changes
Item 7.01 discloses the attachment of a presentation (Exhibit 99.1) used by management in meetings describing the Company. The filing explicitly states that the information contained in the presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated otherwise.
Guidance, Outlook, and Risks
The filing references a presentation dated January 2015 regarding the Company's description but does not contain specific text detailing guidance, outlook, management commentary, risks, contingencies, or unusual items within the body of the 8-K itself.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Presentation dated January 2015) for specific business updates, as the 8-K body only references its existence.
- Note that the presentation materials are not legally "filed" or incorporated by reference in this specific document.
- Confirm the company name discrepancy: The request metadata lists "HARROW, INC.", but the filing text identifies the registrant as "IMPRIMIS PHARMACEUTICALS, INC."
- Review the filing date of January 12, 2015, to ensure alignment with the presentation date.